Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY

v2.4.0.8
STOCKHOLDERS' EQUITY
 12 Months Ended
Sep. 30, 2013
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
5.
STOCKHOLDERS’ EQUITY
 
Common and Preferred Stock
 
As of September 30, 2013, the Company is authorized to issue 165,000,000 shares of stock of which 150,000,000 are common stock at par value of $0.001 per share; the remaining 15,000,000 shares, with a par value of $0.001 per shares are blank-check preferred stock which the Board of Directors are expressly authorized to provide, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
 
As of September 30, 2013, 92,716,562 shares of common stock were issued and outstanding and no shares of preferred stock were issued or outstanding.
 
As of September 30, 2013, CNS California is authorized to issue 100,000,000 no par value shares of two classes of stock, 80,000,000 of which was designated as common shares and 20,000,000 of which was designated as preferred shares.
 
As of September 30, 2013, Colorado CNS Response, Inc. is authorized to issue 1,000,000 no par value shares of common stock.
 
As of September 30, 2013, Neuro-Therapy Clinic, Inc., a wholly-owned subsidiary of Colorado CNS Response, Inc., is authorized to issue 10,000 shares of common stock, no par value per share.
 
On September 19, 2012, the BluMont Capital Corp. ITF Northern Rivers Innovation RSP Fund converted $1,900 on principal and interest of their $50,000 August 2012 Note to 40,000 shares of common stock at a conversion price of $0.04718 per share.
 
As a condition of the November 28, 2012 closing of the 2012 Bridge Financing, the Company also entered into Employment Compensation Forfeiture and Exchange Agreements (“Forfeiture and Exchange Agreements”) with three of its executive officers, George Carpenter, Paul Buck and Michael Darkoch. Pursuant to these agreements, the executives agreed to waive receipt of and release the Company from the payment of 50% of their salaries accrued from August 31, 2010 to September 30, 2012 (amount waived was $56,250 for George Carpenter, $66,083 for Paul Buck and $43,333 for Michael Darkoch), in consideration for which the Company agreed to issue to such executives a certain number of shares of its common stock (56,250 for George Carpenter, 66,083 for Paul Buck and 43,333 for Michael Darkoch). Any remaining accrued salary remains outstanding and shall be paid (i) from time to time at the discretion of the Board of Directors to the extent the Board of Directors determines that such payment will not jeopardize the ability of the Company to continue as a going concern; or (ii) upon the closing of any single financing transaction (including a single financing transaction that contemplates multiple closings) in which the Company receives proceeds of $5 million or more. Additionally, where applicable, the executives agreed to waive receipt of and release the Company from the payment of any previously approved bonus award. Under the agreements, the Company agreed to indemnify the executives for all federal and state income tax payable and actually paid by the executive related directly to the receipt of the common stock, the per share value of which was not expected to be more than the conversion price of the October 2012 Notes which was $0.04718 per share.
 
From January 18, 2013 through September 30, 2013 the $1,998,200 of October 2012 Note holders converted all their debt and interest thereon into 44,085,044 shares of common stock, par value $0.001, at a conversion price of $0.04718 per share. (Refer to Note 7. Related Party Transactions)
 
On January 31, 2013, the SAIL Capital Partners converted all their notes convertible at $1.00 in the aggregate principal amount of $1,250,000 and $219,800 of interest thereon into 1,469,816 shares of common stock. Of these conversions $250,000 was an October 2010 Note together with interest of $53,300 converted into 303,313 shares of common stock at a conversion price of $1.00 per share. $1,000,000 in aggregate were six January 2011 Notes together with interest of $166,500 which converted into 1,166,503 shares of common stock at a conversion price of $1.00.
 
From February 22, 2013 through April 1, 2013, 19 accredited investors purchased an aggregate of 4,180,000 shares of common stock at a price of $0.25 per share in a private placement. The Company received gross aggregate cash proceeds of $1,045,000. (Refer to Note 7. Related Party Transactions)
 
On March 26, 2013 the Board resolved to amend the Company’s Charter in order to:
 
1)
increase the number of shares of common stock authorized for issuance under the Charter from 100,000,000 to 150,000,000; and
2)
create one or more series of preferred stock, par value $0.001 per share, and authorize 15,000,000 shares of such preferred stock for issuance.
 
This amendment to the Charter was approved by more than 80% of the shareholders eligible to vote at the annual meeting of shareholders which was held on May 23, 2013.
 
From May 23, 2013, through September 12, 2013, 23 accredited investors purchased an aggregate of 8,000,000 shares of common stock, par value $0.001, at a price of $0.25 per share pursuant to a private placement. The Company received gross aggregate cash proceeds of $2,000,000. (Refer to Note 7. Related Party Transactions)
 
On August 12, 2013, pursuant to an offer to all holders of debt convertible into common stock at $1.00 per share, all holders agreed to convert $7,723,300 of convertible debt, which included $1,359,400 interest thereon, into 30,893,419 shares of common stock, par value $0.001 per share, at a per share price of $0.25. (Refer to Note 7. Related Party Transactions)
 
Below is a summary of all promissory notes conversions:
 
Conversion of Notes
 
Shares of
Common
Stock
 
Conversion
Date
 
Conversion
Price
 
Principal
Amount
 
Interest
 
Total
 
Fiscal Year 2012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
October 2012 Notes: Unsecured convertible notes
 
 
40,000
 
 
09/19/12
 
$
0.04718
 
$
1,800
 
$
100
 
$
1,900
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year 2013
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
October 2010 Notes: Senior
 
 
303,313
 
 
01/31/13
 
$
1.00
 
$
250,000
 
$
53,300
 
$
303,300
 
subordinated convertible notes
 
 
13,943,539
 
 
08/12/13
 
$
0.25
 
 
2,773,900
 
 
712,000
 
 
3,485,900
 
Total October 2010 Notes:
 
 
14,246,852
 
 
 
 
 
 
 
$
3,023,900
 
$
765,300
 
$
3,789,200
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
January 2011 Notes:
 
 
1,166,503
 
 
01/31/13
 
$
1.00
 
$
1,000,000
 
$
166,500
 
$
1,166,500
 
Subordinated convertible notes
 
 
7,336,500
 
 
08/12/13
 
$
0.25
 
 
1,500,000
 
 
334,100
 
 
1,834,100
 
Total January 2011 Notes:
 
 
8,503,003
 
 
 
 
 
 
 
$
2,500,000
 
 
500,600
 
$
3,000,600
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
October 2011 Notes: Subordinated convertible notes
 
 
9,205,680
 
 
08/12/13
 
$
0.25
 
$
2,000,000
 
$
301,400
 
$
2,301,400
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
February 2012 Notes: Unsecured convertible note
 
 
407,700
 
 
08/12/13
 
$
0.25
 
$
90,000
 
$
11,900
 
$
101,900
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
October 2012 Notes: Unsecured convertible notes
 
 
44,085,044
 
01/18/13 through 09/30/13
 
$
0.04718
 
$
1,998,200
 
$
81,800
 
$
2,080,000
 
Total of Notes Converted in Fiscal 2013
 
 
76,448,279
 
 
 
 
 
 
 
$
9,612,100
 
$
1,661,000
 
$
11,273,100
 
Total of Notes Converted
 
 
76,488,279
 
 
 
 
 
 
 
$
9,613,900
 
$
1,661,100
 
 
11,275,000
 
 
From August 30, 2013, through September 30, 2013, pursuant to a subscription agreement, 10 vendors converted an aggregate $502,100 of payable into 2,008,318 shares of common stock, par value $0.001, at a price for $0.25 per share. (Refer to Note 7. Related Party Transactions)
 
Stock-Option Plan
 
On August 3, 2006, CNS California adopted the CNS California 2006 Stock Incentive Plan (the “2006 Plan”). The 2006 Plan provides for the issuance of awards in the form of restricted shares, stock options (which may constitute incentive stock options (ISO) or non-statutory stock options (NSO), stock appreciation rights and stock unit grants to eligible employees, directors and consultants and is administered by the board of directors. A total of 333,334 shares of stock were initially reserved for issuance under the 2006 Plan.
 
 The 2006 Plan initially provided that in any calendar year, no eligible employee or director shall be granted an award to purchase more than 100,000 shares of stock. The option price for each share of stock subject to an option shall be (i) no less than the fair market value of a share of stock on the date the option is granted, if the option is an ISO, or (ii) no less than 85% of the fair market value of the stock on the date the option is granted, if the option is a NSO; provided, however, if the option is an ISO granted to an eligible employee who is a 10% shareholder, the option price for each share of stock subject to such ISO shall be no less than 110% of the fair market value of a share of stock on the date such ISO is granted. Stock options have a maximum term of ten years from the date of grant, except for ISOs granted to an eligible employee who is a 10% shareholder, in which case the maximum term is five years from the date of grant. ISOs may be granted only to eligible employees.
 
On March 3, 2010, the Board of Directors approved an amendment to the 2006 Plan which increased the number of shares reserved for issuance under the 2006 plan from 333,334 to 666,667 shares of stock. The amendment also increased the limit on shares issued within a calendar year to any eligible employee or director from 100,000 to 133,333 shares of stock. The amendment was approved by shareholders at the annual meeting held on April 27, 2010.
 
On March 22, 2012, our Board of Directors approved the CNS Response, Inc. 2012 Omnibus Incentive Compensation Plan (the “2012 Plan”), reserved 333,334 shares of stock for issuance and approved the grant of options to purchase 42,670 shares of common stock pursuant to such plan at an exercise price of $3.00 per share, including options to purchase 8,334 shares to each of our directors Zachary McAdoo and Maurice DeWald.
 
On December 10, 2012, the Board approved the amendment of the Company’s 2012 Omnibus Incentive Compensation Plan (the “2012 Plan”) to increase the shares authorized for issuance under the 2012 Plan from 333,334 shares to 5,500,000 shares and granted to each of its three existing members as well as to each of the four New Board Members options to purchase 250,000 shares of its common stock pursuant to the 2012 Plan at an exercise price of $0.04718 per share. The options vest evenly over 36 months starting from the date of grant. The Board furthermore granted to each of the five former directors who had departed the Board effective November 30, 2012, (George Carpenter, Henry Harbin, George Kallins, David Jones, and Maurice DeWald), options to purchase 25,000 shares of its common stock pursuant to the 2012 Plan at an exercise price of $0.04718 per share. These options to former directors are fully vested. Finally, the Board granted to the Company’s executive officers options to purchase shares of its common stock pursuant to the 2012 Plan at an exercise price of $0.04718 per share as follows: George Carpenter 1,200,000 shares, Paul Buck 1,400,000 shares and Michael Darkoch 920,000 shares. These options vest in increments of 12.5% at the beginning of each quarter starting from the date of grant.
 
Based on the volume of shares traded on the open market, during the period October 1, 2012 through to December 10, 2012, the date of the option grant, management judged that the Company’s stock was not actively traded as only $15,000 worth of stock was traded on 11 of 48 trading days during this period at prices ranging from $0.76 to $0.83. In a contemporaneous transaction, Senior Secured Convertible Notes (“October 2012 Notes”) with a conversion price of $0.04718 were purchased by accredited third party investors. Given the very low volume of stock which was not actively traded, compared to the volume of October 2012 Notes purchased, management’s judgment was that the pricing of the October 2012 Notes at $0.04718 represented a better determinant of fair value of the Company’s common stock on December 10, 2012.
 
On January 14, 2013, the Board granted options to purchase 1,960,000 shares of common stock to members of staff and 1,600,000 share of common stock to key consultants. The options granted to staff vest evenly over 48 months starting on the date of grant. The options granted to consultants vest evenly over 36 months starting on the date of grant. All these options have an exercise price of $0.04718 per share.
 
Based on the volume of shares traded on the open market, during the period October 1, 2012 through to January 14, 2013, the date of the option grant, management judged that the Company’s stock was not actively traded as only $36,700 worth of stock was traded on 21 of 50 trading days during this period at prices ranging from $0.49 to $2.50. There had been a recent transaction which closed on November 30, 2012 whereby $2 million of Senior Secured Convertible Notes (“October 2012 Notes”) with a conversion price of $0.04718 were purchased by accredited third party investors. Given the very low volume of stock which was not actively traded, compared to the volume of October 2012 Notes purchased, management’s judgment was that the pricing of the October 2012 Notes at $0.04718 represented a better determinant of fair value of the Company’s common stock on January 14, 2013.
 
On March 26, 2013, the Board approved the amendment of the Company’s 2012 Plan to increase the shares authorized for issuance under the 2012 Plan from 5,500,000 shares to 15,000,000 shares. The Board also granted options to purchase 250,000 shares of common stock to Thomas Tierney upon his election to be Chairman of the Board of Directors. These options granted to Mr. Tierney vest evenly over 36 months starting on the date of grant and have an exercise price of $0.25 per share.
 
Based on the volume of shares traded on the open market, during the period January 1, 2013 through to March 26, 2013, the date of the option grant, management judged that the Company’s stock was not actively traded as only $283,400 worth of stock was traded on 22 of 58 trading days during this period at prices ranging from $0.46 to $0.83. There was a contemporaneous transaction whereby $695,000 worth of a $2.5 million private placement offering of common stock at a price of $0.25 per share were purchased by accredited third party investors. Given the low volume of stock which was not actively traded, compared to the volume of the private placement of common stock, management’s judgment was that the pricing of the private placement of common stock at $0.25 per share represented a better determinant of fair value of the Company’s common stock on March 26, 2013.
 
The 2012 Plan, as amended, was approved by our shareholders at the 2013 annual meeting held on May 23, 2013.
 
As of September 30, 2013, 70,825 options were exercised and there were 501,924 options and 6,132 restricted shares outstanding under the amended 2006 Plan leaving 87,786 shares which will not be issued as the 2006 Plan is frozen. 9,247,670 options have been issued under the 2012 Plan, none of which have been exercised, leaving 5,250,406 available for issuance.
 
The Company estimates the fair value of each option on the grant date using the Black-Scholes model.   The following assumptions were made in estimating the fair value:
 
 
 
2013
 
 
2012
 
 
Annual dividend yield
 
 
-
 
 
 
-
 
 
Expected life (years)
 
 
5
 
 
 
5
 
 
Risk-free interest rate
 
 
0.62% - 0.79
%
 
 
1.13
%
 
Expected volatility
 
 
380% - 393
%
 
 
274
%
 
Fair value of options granted
 
$
0.05 - 0.25
 
 
$
3.00
 
 
 
Stock-based compensation expense is recognized over the employees’ or service provider’s requisite service period, generally the vesting period of the award. Stock-based compensation expense included in the accompanying statements of operations for the fiscal years ended September 30, 2013 and 2012 is as follows:
 
 
 
For the fiscal years ended
September 30,
 
 
 
2013
 
2012
 
Cost of Neurometric Services revenues
 
$
10,600
 
$
10,200
 
Research
 
 
92,700
 
 
99,200
 
Product Development
 
 
113,300
 
 
72,500
 
Sales and marketing
 
 
155,500
 
 
196,800
 
General and administrative
 
 
885,200
 
 
972,100
 
Total
 
$
1,257,300
 
$
1,350,800
 
 
Total unrecognized compensation as of September 30, 2013 amounted to $793,200.
 
A summary of stock option activity is as follows:
 
 
 
Number of
Shares
 
Weighted Average
Exercise Price
 
Outstanding at September 30, 2011
 
 
524,201
 
$
19.88
 
 
 
 
 
 
 
 
 
Granted
 
 
42,670
 
 
3.00
 
Exercised
 
 
-
 
 
-
 
Forfeited
 
 
(20,125)
 
 
24.08
 
Outstanding at September 30, 2012
 
 
546,746
 
$
17.08
 
 
 
 
 
 
 
 
 
Granted
 
 
9,205,000
 
 
0.05
 
Exercised
 
 
-
 
 
-
 
Forfeited
 
 
(2,152)
 
 
14.10
 
Outstanding at September 30, 2013
 
 
9,749,594
 
$
1.00
 
 
Following is a summary of the status of options outstanding at September 30, 2013:
 
Exercise
Price
 
Number
of Shares
 
Weighted
Average
Contractual
Life
 
Weighted
Average
Exercise
Price
 
Vested at
September
30, 2013
 
Weighted
Average
Remaining
Life
(Years)
 
Aggregate
Intrinsic
Value at $0.25
 price per
 share at
September
30, 2013
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
0.04718
 
 
8,955,000
 
 
10 years
 
$
0.04718
 
 
3,138,611
 
 
9.2
 
$
1,816,254
 
$
0.25
 
 
250,000
 
 
10 years
 
 
0.25
 
 
48,611
 
 
9.5
 
 
-
 
$
3.00
 
 
42,670
 
 
10 years
 
 
3.00
 
 
23,706
 
 
8.5
 
 
-
 
$
3.60
 
 
28,648
 
 
10 years
 
 
3.60
 
 
28,648
 
 
2.9
 
 
-
 
$
3.96
 
 
32,928
 
 
10 years
 
 
3.96
 
 
32,928
 
 
2.9
 
 
-
 
$
9.00
 
 
4,525
 
 
10 years
 
 
9.00
 
 
4,525
 
 
3.1
 
 
-
 
$
12.00
 
 
28,535
 
 
10 years
 
 
12.00
 
 
25,723
 
 
6.7
 
 
-
 
$
14.10
 
 
10,000
 
 
10 years
 
 
14.10
 
 
6,458
 
 
7.5
 
 
-
 
$
15.30
 
 
1,373
 
 
10 years
 
 
15.30
 
 
1,373
 
 
5.0
 
 
-
 
$
16.50
 
 
262,441
 
 
10 years
 
 
16.50
 
 
242,476
 
 
6.4
 
 
-
 
$
17.70
 
 
953
 
 
10 years
 
 
17.70
 
 
953
 
 
2.9
 
 
-
 
$
24.00
 
 
4,667
 
 
10 years
 
 
24.00
 
 
4,667
 
 
4.2
 
 
-
 
$
26.70
 
 
32,297
 
 
10 years
 
 
26.70
 
 
32,297
 
 
4.0
 
 
-
 
$
28.80
 
 
11,767
 
 
10 years
 
 
28.80
 
 
11,767
 
 
4.5
 
 
-
 
$
32.70
 
 
83,790
 
 
10 years
 
 
32.70
 
 
83,790
 
 
3.9
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
9,749,594
 
 
 
 
$
1.00
 
 
3,686,533
 
 
9.0
 
$
1,816,254
 
 
We have entered into agreements on June 3, 2011 with the majority of our 2006 Plan option holders pursuant to which holders of options to purchase an aggregate of 439,689 shares of our common stock, at exercise prices ranging from $3.60 per share to $32.70 per share, have agreed to amend their options to permit exercise only in cash and to limit the period during which the options may be exercised post-termination to 90 days (for employees) and twelve months (for consultants).
 
We have agreed to freeze any further grants or exercises of securities under the 2006 Plan and adopt the 2012 Stock Incentive Plan, which was approved at the 2013 Annual Meeting of Stockholders held on May 23, 2013.

Warrants to Purchase Common Stock
 
  The warrant activity for the period starting October 1, 2011, through September 30, 2013, is described as follows:
 
Warrants
 
 
Exercise Price
 
 
Issued, Surrendered or Expired in Connection With:
 
980,390
 
 
 
 
 
 
Warrants outstanding at October 1, 2011
 
613,782
 
 
$
3.00
 
 
As a result of the issuance of October 2011 Notes at a conversion of $3.00 and associated warrants to purchase common stock at an exercise price of $3.00, the ratchet provision in the October and January 2011 Notes was triggered with the resultant adjustment in the number of shares convertible at the lowered conversion price of $3.00 down from $9.00 and the consequential adjustment in the number of warrants issued to the October and January Note Holders. These warrants were subsequently forfeited pursuant to the Amended and Restated Consent, Note Amendment and Warrant Forfeiture Agreement dated October 24, 2012.
 
31,112
 
 
$
1.00
 
 
As mentioned above, the ratchet provision in the issued placement agent warrants was also triggered with the resultant adjustment in the number of warrants being issued to the placement agents. Effective on November 20, 2012 the holders of placement agent warrants agreed to remove the ratchet feature in exchange for lowering the conversion price to $1.00 per share down from $3.00 per share. This resulted in the elimination of warrant liabilities as of such date.
 
(2,823
)
 
$
0.30
 
 
Warrants were surrendered in a cash exercise for 2,823 shares.
 
696,673
 
 
$
3.00
 
 
These warrants were issued to 11 investors who purchased notes for $2,000,000 pursuant to the 2011 Bridge Purchase Agreement (October 2011 Notes).  These warrants were subsequently forfeited pursuant to the Amended and Restated Consent, Note Amendment and Warrant Forfeiture Agreement dated October 24, 2012.
 
Warrants
 
 
Exercise Price
 
 
Issued, Surrendered or Expired in Connection With:
 
5,334
 
 
$
1.00
 
 
These warrants were issued to Monarch Capital who acted as placement agents in raising $80,000 from two investors who purchased pursuant to the 2011 Bridge Note Purchase Agreement (October 2011 Notes). Effective on November 20, 2012 the holders of placement agent warrants agreed to remove the ratchet feature in exchange for lowering the conversion price to $1.00 per share down from $3.00 per share. This resulted in the elimination of warrant liabilities as of such date.
 
15,167
 
 
$
1.00
 
 
These warrants were issued to Innerkip Capital Management who acted as placement agents in raising $650,000 from three investors who purchased pursuant to the 2011 Bridge Note Purchase Agreement (October 2011 Notes). Effective on November 20, 2012 the holders of placement agent warrants agreed to remove the ratchet feature in exchange for lowering the conversion price to $1.00 per share down from $3.00 per share. This resulted in the elimination of warrant liabilities as of such date. 
 
(175,195
)
 
 
$0.30 to $54.0
 
 
Warrants expired
 
2,164,440
 
 
 
 
 
 
Warrants outstanding at September 30, 2012
 
(1,617,345
)
 
$
3.00
 
 
Warrants forfeited pursuant to the Amended and Restated Consent, Note Amendment and Warrant Forfeiture Agreement dated October 24, 2012
 
127,173
 
 
$
0.04718
 
 
These warrants were issued to Monarch Capital who acted as placement agents in raising $60,000 from one investor who purchased October 2012 Notes pursuant to the 2012 Bridge Note October Purchase Agreement.
 
519,288
 
 
$
0.04718
 
 
These warrants due to be issued to Tony Pullen who acted as placement agents in raising $350,000 from three investors who purchased October 2012 Notes pursuant to the 2012 Bridge Note October Purchase Agreement.
 
152,000
 
 
$
0.275
 
 
These warrants were issued to Monarch Capital who acted as placement agents in raising $380,000 from twelve accredited investors who purchased common stock, par value $0.001 per share, in private placement agreements dated February 20, 2013 and May 23, 2013.
 
100,000
 
 
$
0.25
 
 
These warrants were issued to D&D Securities Inc. in connection with the Company’s private offering to select accredited investors of shares of restricted common stock at a private of $0.25 per share, in a private placement agreement dated February 20, 2013.
 
52,000
 
 
$
0.275
 
 
These warrants were issued to Monarch Capital who acted as placement agents in raising $520,000 from five accredited investors who purchased common stock, par value $0.001 per share, in a private placement agreement dated May 23, 2013.
 
1,497,556
 
 
$
3.03
 
 
Warrants outstanding at September 30, 2013
 
At September 30, 2013, there were warrants outstanding to purchase 1,497,556 shares of the Company’s common stock. The exercise price of the outstanding warrants range from $0.04718 to $9.90 with a weighted average exercise price of $3.03.  The warrants expire at various times starting 2014 through 2018.